trial

Treatment Development Targeting Severe and Persistent Negative Symptoms

NCTId NCT01550666
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 96 (actual)
Sponsored by The University of Texas Health Science Center at San Antonio
Primary completion 2014-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
96 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2011-01
Primary completion
2014-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
MOVE

Sponsors

The University of Texas Health Science Center at San AntonioLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Dawn' I Velligan, Ph.D.Principal Investigator

Sites

1 total
San Antonio, United States

Facts & assertions

4 sourced
Enrollment
96
Phase
NA
Primary Completion Date
2014-08
Status
COMPLETED
relationships
The graph out of here
drug
MOVE
drug
lead_sponsor
The University of Texas Health Science Center at San Antonio
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Dawn' I Velligan, Ph.D.
person